Syndrome In Postmenopausal Women Research Articles

Effects of muscle strength training in postmenopausal women with metabolic syndrome. Systematic review

During menopause, the risk of developing metabolic syndrome increases exponentially because of hormonal changes and old age. The aim is to perform a systematic review of randomized clinical trials to the effects of muscle strength training on the different parameters of the metabolic syndrome in postmenopausal women. A systematic review of the literature was performed in Pubmed, ScienDirect and SportDiscus using the words: Resistance training and metabolic syndrome or strength training and menopause, giving a result of 530 articles and selecting 9 of them that met the established criteria. All studies were performed in postmenopausal women, implementing muscle strength training with control group, evaluation of some component of metabolic syndrome, and with stated intensity. The studies were then evaluated using the PEDro scale. The results show that muscle strength training has been shown to have positive effects on the postmenopausal population, increasing muscle mass, improving glycemic control, regulating blood lipids, blood pressure and above all the overall metabolic syndrome score, being a safe strategy to implement in this population. According to this review, the parameters for prescribing the intensity of muscle strength exercise have not yet been determined.

The relationship between menopausal symptoms and metabolic syndrome in postmenopausal women

The most common symptoms during menopausal transition and menopause are vasomotor symptoms. We aimed to investigate the relationship between menopausal symptoms and metabolic syndrome (MetS) in postmenopausal women. Two hundred and fifty-four and 317 postmenopausal women were in the MetS and non-MetS groups, respectively. The total menopause rating scale and psychological subscale scores were higher in the MetS group than the non-MetS group, and the differences were significant (p < .05). A positive correlation was found between the abdominal circumferences, systolic-diastolic blood pressures, triglycerides and total MRS scores. However, a significant positive correlation was found between the abdominal circumference and total urogenital scores (p = .008).Impact statementWhat is already known on this subject? MetS and its dominant component (abdominal obesity) significantly increase the prevalence and severity of menopausal symptoms. Data regarding the relationship between metabolic syndrome (MetS) and vasomotor symptoms remain limited.What do the results of this study add? We showed that sleeping problems, depressive symptoms and bladder problems were more frequently encountered in the MetS group than in the non-MetS group (p<0.05).What are the implications of these findings for clinical practice and/or further research? There is a need for more randomised controlled studies to demonstrate the relationship between MetS and the severity of menopausal symptoms.

Vitamin D and thiol-disulfide homeostasis levels in postmenopausal women with overactive bladder syndrome.

This study aimed to find a relationship between vitamin D concentration and thiol-disulfide homeostasis in the pathophysiology of overactive bladder (OAB) syndrome in postmenopausal women. A total of 76 postmenopausal women, referred for routine controls, were recruited between January and March 2018 to participate in this study. Participants with an overactive bladder questionnaire (OAB-q) score of >11 (n = 34) were included in the OAB syndrome group, while those with a score of <5 (n = 42) were included in the control group. Serum total antioxidant capacity, ischemia-modified albumin, C-reactive protein, 25-hydroxy vitamin D levels, and thiol-disulfide homeostasis were measured. Patients with OAB syndrome had waist circumferences of 106 ± 11 cm, and their body mass indexes (BMIs) were 30.8 ± 4.8 kg/m2. The control groups' waist circumferences were 102 ± 11 cm and their BMIs were 28.9 ± 4.3 kg/m2 (p = 0.069 and p = 0.098, respectively). The level of vitamin D in the control group was 33.7 (IQR: 30.7) nmol/L and 27.0 (IQR: 27.5) nmol/L (p = 0.081) in the OAB syndrome group. We were not able to demonstrate with certainty any significant relationships between serum 25-hydroxy vitamin D levels and thiol-disulfide homeostasis parameters and OAB syndrome.

Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative.

ImportanceCarpal tunnel syndrome (CTS) is a common and debilitating condition that commonly affects postmenopausal women.ObjectiveTo determine the effect of menopausal hormone therapy (HT) in healthy postmenopausal women on CTS risk.DesignWe conducted a secondary analysis of the Women’s Health Initiative’s (WHI) HT trials linked to Medicare claims data. Separate intention-to-treat analyses were performed for the two trials; the conjugated equine estrogens alone (CEE alone) and the trial of CEE plus medroxyprogesterone acetate (MPA) trial. (ClinicalTrials.gov, NCT number): NCT00000611.SettingTwo randomized, double-blind, placebo-controlled trials conducted at 40 US clinical centers.ParticipantsThe sample size included in the analysis was 16,053 community-dwelling women aged ≥65 years at study entry or those who later aged into Medicare eligibility, and who were enrolled in Medicare (including Part A and/or Part B coverage).InterventionWomen with hysterectomy were randomized to 0.625 mg/d of conjugated equine estrogens (CEE) or placebo (n = 8376). Women without hysterectomy were randomized to estrogen plus progestin (E+P), given as CEE plus 2.5 mg/d of medroxyprogesterone acetate (n = 14203).Main outcome(s)The primary outcome was incident CTS and the secondary outcome was therapeutic CTS procedure occurring during the intervention phases of the trials.ResultsA total of 16,053 women were randomized in both trials. During mean follow up of 4.5 ± 2.8 years in the CEE trial (n = 6,833), there were 203 incident CTS cases in the intervention and 262 incident CTS cases in the placebo group (HR, 0.78; 95% CI, 0.65–0.94; P = 0.009). The CEE+MPA trial (n = 9,220) followed participants for a mean of 3.7 ± 2.3 years. There were 173 incident CTS cases in the intervention compared to 203 cases in the placebo group (HR, 0.80, 95% CI, 0.65–0.97; P = 0.027).ConclusionsThese findings suggest a protective effect of menopausal HT on the incidence of CTS among postmenopausal women. A potential therapeutic role for other forms of estrogen therapy in the management of CTS warrants future research.

Sex hormone therapy's effect on dry eye syndrome in postmenopausal women: A meta-analysis of randomized controlled trials.

The purpose of the study to assess the efficacy of sex hormone therapy in the treatment of dry eye syndrome in postmenopausal women.The following electronic databases were searched without language restrictions: PubMed, Embase, Cochrane, and the Chinese Biomedical Database. Two reviewers collected all the literature, which was searched for relevance in English and Chinese from January 1990 to July 2017. Both of the reviewers screened documents independently, identifying the studies that met the inclusion criteria. Then, the included studies were evaluated, and the data were extracted and conversed dependently. Finally, Review Manager 5.3 (offered by the Cochrane collaboration) was used to complete the meta-analysis. An integrated mean difference (MD) with its corresponding 95% confidence interval (CI) was calculated.A total of 358 patients with dry eye were enrolled in 7 randomized controlled trials (RCTs). We observed statistically significant improvements in the Schirmer's test scores (MD, 2.06; 95% CI, 0.74–4.46; I2 = 97%; P = .006) after sex hormone treatment. However, the scores for tear breakup time (TBUT) (MD, 1.28; 95% CI, −1.03 to 4.68; I2 = 99%; P = .21) and the ocular comfort index (OCI) (MD, −1.12; 95% CI, −4.42 to 1.98; I2 = 95%; P = .48) were not improved.This meta-analysis of 7 RCTs suggests that sex hormone therapy may be associated with better Schirmer's test scores. However, no significant differences were detected in the TBUT and OCI test scores. Consequently, sex hormone therapy has a potentially useful role in the effective management of postmenopausal women with dry eye syndrome.

Estrogen receptor 1 gene polymorphisms are associated with metabolic syndrome in postmenopausal women in China

BackgroundMetabolic syndrome (MetS) includes obesity, diabetes, dyslipidemia and hypertension. Its incidence is rapidly increasing worldwide, particularly in postmenopausal women. Estrogens regulate glucose homeostasis and lipid metabolism via estrogen receptors 1 (ESR1) and 2 (ESR2). The current study aimed to elucidate associations of MetS with ESR1 and ESR2 gene polymorphisms in postmenopausal Chinese women.MethodsThis case-control study included 304 postmenopausal women (154 and 150 control and MetS patients, respectively). Clinical indicators related to MetS were assessed. Two ESR1 (PvuII and XbaI) and two ESR2 (RsaI and AluI) polymorphisms were evaluated by polymerase chain reaction (PCR)-restriction fragment length polymorphism analysis.ResultsESR1 polymorphisms were significantly different between MetS patients and healthy controls. G allele frequency for the XbaI polymorphism was significantly higher in patients than in control patients (p = 0.004, OR = 1.610, 95%CI 1.169–2.18). The haplotypes A–T (p = 0.015) and G–C (p = 0.024) showed significant differences. The minor alleles of the XbaI and PvuII gene polymorphisms in both homozygous and heterozygous forms showed associations with elevated waist circumference, fasting serum insulin and HOMA-IR. The minor G allele in homozygous and heterozygous forms of the RsaI and AluI gene polymorphisms showed associations with elevated total cholesterol and LDL-C.ConclusionsIn postmenopausal Chinese women, ESR1 polymorphism and the haplotypes A–T and G–C of XbaI–PvuII are associated with MetS, unlike ESR2 polymorphisms. Patients harboring the G allele of XbaI have elevated BMI, waist circumference, systolic and diastolic BP, FBG, HOMA-IR, total cholesterol, TG, LDL-C and NAFLD (%), and reduced HDL-C.

Burning mouth syndrome in postmenopausal women with self-reported sleep problems

ABSTRACT Objective The aim of this study was to investigate possible relationships among hematologic factors, psychological dimensions, the presence of self-reported sleep problems, and clinical characteristics in patients with burning mouth syndrome (BMS). Methods Twenty-five postmenopausal female patients with primary BMS (aged 55.2 ± 9.6 years) were included. All participants underwent clinical and psychological evaluations and blood sampling. The patients were subdivided according to the absence or presence of the self-reported sleep problems. Results Pain intensity of BMS patients with sleep problems was significantly higher than those without sleep problems, and the severity of oral complaints was correlated with the presence of depression, anxiety, hostility, phobia, and psychosis. Estradiol levels were significantly lower, and FSH and LH levels were higher in BMS patients with sleep problems than those without sleep problems. Discussion BMS patients with sleep problems may suffer inharmonious psychoneuroendocrinological interactions that might worsen oral BMS symptoms.

Relationship between vasomotor symptoms and metabolic syndrome in postmenopausal women.

ObjectiveThis study was performed to compare the vasomotor symptoms and bone mineral density of postmenopausal women with and without metabolic syndrome.MethodsWe performed a cross-sectional study of 200 postmenopausal women attending routine health check-ups at Marmara Faculty of Medicine Pendik Training and Research Hospital from June 2015 to December 2015. The vasomotor symptoms scored were hot flashes and night sweats. Metabolic syndrome was defined using the consensus criteria of the International Diabetes Federation and the American Heart Association/National Heart, Lung, and Blood Institute.ResultsWomen with vasomotor symptoms had no metabolic syndrome and were younger than those without vasomotor symptoms. There was no significant difference in vasomotor symptoms between patients with osteopenia in the femoral neck, total femur, and spine and patients with normal bone mineral density. The vasomotor symptoms were similar between smokers and nonsmokers.ConclusionThe presence of metabolic symptoms is inversely associated with metabolic syndrome in postmenopausal women. Lipid abnormalities and a high body mass index may be important metabolic components associated with these symptoms. No relationship is present between vasomotor symptoms and the bone mineral density of the spine, femoral neck, and total femur.

Higher parity and risk of metabolic syndrome in Korean postmenopausal women: Korea National Health and Nutrition Examination Survey 2010-2012.

We sought to examine whether parity is associated with higher incidence of metabolic syndrome in postmenopausal women. We conducted a cross-sectional study on 4098 Korean postmenopausal women by using nationally representative data from the Korea National Health and Nutrition Examination Survey 2010-2012. Multivariate logistic regression was performed to evaluate the relationship between parity and metabolic syndrome, with adjustment for potential confounding variables. The rate of metabolic syndrome was significantly higher with increasing number of parity, with dose-response relationship in univariate analysis (P <0.001). In addition, higher parity (≥3 live births) was associated with more prevalence of all components of metabolic syndrome compared with two live births (parity 2 vs 3 vs ≥4: 5.5 vs 12.1 and 14.4%, respectively; P < 0.001). However, after adjusting for demographic, socioeconomic, lifestyle and reproductive factors, we found that only higher parity was significantly associated with metabolic syndrome compared with two live births, and failed to show a dose-dependent relationship (parity 2 vs 3 vs ≥4: odds ratio 1 vs 1.404 vs 1.379, respectively; P = 0.043). We also proved that among the components of metabolic syndrome, only waist circumference had a significant positive relationship with parity in a multivariable adjusted model (parity 2 vs 3 vs ≥4: odds ratio 1 vs 1.559 vs 1.656, respectively; P < 0.001). Higher parity was independently associated with a higher risk of metabolic syndrome in postmenopausal women.

Is metabolic syndrome related to postmenopausal osteoporosis? A retrospective study

Aim: To evaluate the difference between postmenopausal women with and without osteoporosis in terms of metabolic syndrome.Methods: A total of 98 postmenopausal women younger than 65 years, were enrolled in the study. According to the bone mineral density examination; 49 participants who had T-score&amp;gt;−2.5 at the spine or/and femoral neck were included in the group without osteoporosis (Group 1), and 49 participants who had T-score≤−2.5 at the spine or/and femoral neck were included in the osteoporosis group (Group 2). Patient’s profile which included all demographic data, particularly anthropometric evaluation and medical history was obtained. Serum fasting glucose, lipid profiles and 25 OH vitamin D levels were also recorded. Results: Age (p=0.001), menopausal age (p=0.003), systolic blood pressure (p=0.004) and diastolic blood pressure (p=0.001) of Group 2 were significantly higher than Group 1. There were no significant difference in terms of body mass index, weight, lipid profiles, serum calcium and serum 25 OH vitamin D levels among the groups (p&amp;gt;0.05 for all). Twenty five (51%) of 49 women in Group 1 and 36 (73%) of 49 women in Group 2 had metabolic syndrome. There was a statistically significant relationship between osteoporosis and the metabolic syndrome (p=0.037). Conclusion: Our results demonstrated that osteoporosis is related with the metabolic syndrome in postmenopausal women.

Association Between the Modified Dietary Approaches to Stop Hypertension and Metabolic Syndrome in Postmenopausal Women Without Diabetes

The aim of our study was to evaluate the association between the dietary approaches to stop hypertension (DASH) and metabolic syndrome in postmenopausal Korean women without diabetes. Our study enrolled postmenopaual women without diabetes (n = 6826). We used the DASH-Korean quartile (KQ) model using six nutrients. For protein, fiber, calcium, and potassium, we scored 1 for the first quartile (1Q), 2 for the second quartile (2Q), 3 for the third quartile (3Q), and 4 for the fourth quartile (4Q). For fat and sodium, we scored 4 for the 1Q, 3 for the 2Q, 2 for the 3Q, and 1 for the 4Q. We defined the sum of the six scores as the DASH-KQ score. Participants were divided into four quartiles (DASH-1Q, DASH-2Q, DASH-3Q, and DASH-4Q), according to the sum of the six DASH-KQ scores. The number of participants with metabolic syndrome in DASH-1Q, DASH-2Q, DASH-3Q, or DASH-4Q was 601 (37.4%), 671 (31.1%), 440 (30.5%), and 492 (30.3%), respectively. The proportion of participants with metabolic syndrome was greatest in DASH-1Q (P < 0.001). Multivariate logistic regression analyses showed that every increase in the DASH-KQ score by 1 exhibited a 0.977-fold odds for metabolic syndrome. DASH-1Q, by DASH-KQ score, had higher odds for metabolic syndrome than the other groups. The lowest quartile of the DASH-KQ score was associated with a higher prevalence of metabolic syndrome in postmenopausal Korean women without diabetes.

The prevalence of metabolic syndrome in postmenopausal women: A systematic review and meta-analysis in Iran

Metabolic syndrome is a set of cardiovascular risk factors that increase the risk of cardiovascular disease, diabetes and mortality. Women are at risk of developing metabolic syndrome as they enter the postmenopausal period. The present systematic review and meta-analysis was conducted to estimate the prevalence of metabolic syndrome in Iranian postmenopausal women. In this systematic review and meta-analysis, 16 national articles published in Persian and English were gathered without time limit. National databases such as SIDs, IranMedex and MagIran, and international databases such as Web of Science, Google Scholar, PubMed and Scopus were used to search the relevant studies. We searched for articles using the keywords “menopause”, “postmenopausal”, “metabolic syndrome”, “MetSyn”, and their combinations. Data were analyzed using the meta-analysis method and the random effects model. Analysis of 16 selected articles with a sample size of 5893 people showed that the prevalence of metabolic syndrome in Iranian postmenopausal women was 51.6% (95% CI: 43–60). The prevalence of metabolic syndrome based on ATP III and IDF criteria was 54% (95% CI: 59–63) and 50% (95% CI: 45–56), respectively. Based on the results of univariate meta-regression analysis, the increase in the mean age of postmenopausal women (p = 0.001) and sample size (p = 0.029), the prevalence of metabolic syndrome increased significantly. More than half of postmenopausal women in Iran suffer from metabolic syndrome. Providing training programs for postmenopausal women to prevent and control cardiovascular disease and its complications seems to be necessary.

History of vasomotor symptoms, extent of coronary artery disease, and clinical outcomes after acute coronary syndrome in postmenopausal women.

Vasomotor symptoms (VMS) during menopausal transition have been linked to a higher burden of cardiovascular risk factors, subclinical vascular disease, and subsequent vascular events. We aim to investigate the association of VMS with the extent of coronary disease and their prognostic role after an acute coronary syndrome. The Ladies Acute Coronary Syndrome study enrolled consecutive women with an acute coronary syndrome undergoing coronary angiography. A menopause questionnaire was administered during admission. Angiographic data underwent corelab analysis. Six out of 10 enrolling centers participated in 1-year follow-up. Outcome data included the composite endpoint of all-cause mortality, recurrent myocardial infarction, stroke, and rehospitalization for cardiovascular causes within 1 year. Of the 415 women with available angiographic corelab analysis, 373 (90%) had complete 1-year follow-up. Among them, 202 women had had VMS during menopausal transition. These women had the same mean age at menopause as those without VMS (50 years in both groups), but were younger at presentation (median age 71 vs 76 years; P < 0.001), despite a more favorable cardiovascular risk profile (chronic kidney dysfunction 4.5% vs 15.9%; P = 0.001; prior cerebrovascular disease 4.5 vs 12.2%; P = 0.018). Extent of coronary disease at angiography was similar between groups (mean Gensini score 49 vs 51; P = 0.6; mean SYNTAX score 14 vs 16; P = 0.3). Overall cardiovascular events at 1 year did not differ between groups (19% vs 22%; P = 0.5). In postmenopausal women with an acute coronary syndrome, a history of VMS was associated with younger age at presentation, despite a lower vascular disease burden and similar angiographically defined coronary disease as compared with women without VMS. No difference could be found in terms of overall clinical outcomes. These results should be interpreted cautiously as all analyses were unadjusted and did not account for risk factor differences between women with and without a history of VMS.

How Exercise and Dietary Intervention Affect the Outcome of Osteosarcopenic Obesity Syndrome?

Osteosarcopenic obesity (OSO) is described as the simultaneous presence of osteopenia/osteoporosis, sarcopenia, and increased adiposity. Over time, older adults with OSO syndrome might be at greater risk for loss of physical function and bone fractures. Furthermore, a sedentary lifestyle, inadequate nutrition, pharmaceutical drugs, and chronic conditions encompass the multifactorial nature of OSO syndrome. Physical activity and a healthy diet play a crucial role in management and treatment of OSO syndrome. Research has shown that even low-intensity physical activity or daily habitual activity can maintain bone mineral density, muscle strength, and improve muscle quality, and reduce adiposity. However, older adults with high risk of fall and injuries require tailored exercise intensity. Also, balanced daily intake of vitamin D, calcium, and protein is important in prevention and treatment of OSO syndrome in postmenopausal women. Effective measurement of bone mass, muscle mass, and strength is required when detecting OSO syndrome and to evaluate the balance, strength and endurance of elder individuals and severity of the condition.

Effects of Age at First Childbirth and Other Factors on Central Obesity in Postmenopausal Women: The 2013-2015 Korean National Health and Nutrition Examination Survey.

BackgroundWaist circumference is one of the key components of metabolic syndrome. Recent studies demonstrated that the reproductive profile was associated with metabolic syndrome in postmenopausal women. This study focused on the association between central obesity and age at first childbirth. It also considered other factors associated with central obesity in postmenopausal women.MethodsThis study was based on the 2013–2015 Korean National Health and Nutrition Examination Survey and involved 3,143 naturally postmenopausal women. These women were divided into three groups according to their age at first childbirth: 19 years or younger (n=252), 20–29 years (n=2,695), and 30 years or older (n=196). Multivariate analysis using logistic regression was performed to evaluate the effects of various reproductive factors, including other confounding factors.ResultsDuring adjustment for confounding factors, in the early age at first childbirth group, odds ratios (95% confidence intervals) for central obesity decreased. In the final model, younger age at first childbirth was not significantly related to central obesity (waist circumference more than 85 cm) in naturally postmenopausal women after adjusting for other confounding factors.ConclusionYounger age at first childbirth was not significantly associated with central obesity after adjustment for confounding factors.

TNF-α contributes to postmenopausal osteoporosis by synergistically promoting RANKL-induced osteoclast formation

Previous studies showed that inflammatory cytokines promote osteoclast formation, characterized by the function of bone resorption. However, it remains unclear whether inflammatory factors contribute to osteoporosis syndrome in postmenopausal women. Here, we found that postmenopausal women with osteoporosis (PO) had increased levels of TNF-α, compared with those without osteoporosis. TNF-α is highly correlated with the RANK and estrogen levels in PO patients. in vitro, TNF-α synergistically promotes RANKL-induced osteoclast formation by activation of NF-κB and PI3K/Akt signaling. Moreover, inhibition of PI3K/Akt totally blocked the synergistic effects of TNF-α on NF-κB activation as well as osteoclast formation. Together, these results demonstrate that TNF-α synergistically promotes RANKL-induced osteoclasts formation through activation of PI3K/Akt signaling, which ultimately contributes to osteoporosis syndrome in postmenopausal women.

Особенности проявлений климактерического синдрома у женщин в постменопаузальный период в современных условиях

The objective: investigation was to study the expression of climacteric syndrome in postmenopausal women in Azerbaijan. Materials and methods.There were 120 postmenopausal women examined the average age of the women was 60.29±0.69 years. The duration of postmenopausal period was within 10.33±0.67 years. In 45 (37.5%) of women the duration of postmenopausal period varied between 2 and 5 years, 16 (13%) it was between 6 and 9 years, while in 59 (49.2%) of women it was more than 10 years. Results. As a result of the conducted studies, the frequency and severity of vegetative, metabolic-endocrine, psychoemotional manifestations of menopausal syndrome in the examined women in the postmenopausal period were determined. Conclusion. It was that autonomic nervous expressions of climacteric syndrome comprised 28.8±0.46, endocrine symptoms 22.6±0.8, emotional expressions were 7.8±4.6. The average evaluation of climacteric syndrome was 59.2±2.11, that corresponds to the moderate degree of expression of climacteric syndrome. Key words: postmenopausal period, autonomic nervous dystonia, endocrine symptoms, psycho emotional expressions, involutive process.

Association of Leptin: Adiponectin ratio and metabolic risk markers in postmenopausal women

Leptin and adiponectin play an important role in the regulation of body weight and energy homeostasis. The purpose of the present study was to ascertain the relationship between leptin to adiponectin ratio (L:A) and metabolic risk factors in postmenopausal women.This is a cross sectional case-control study. A total of 523 postmenopausal women were recruited for the study 270 postmenopausal women with metabolic syndrome and 253 apparently healthy control postmenopausal women without metabolic syndrome. Biochemical and Anthropometrical parameters were measured. Leptin and adiponectin levels were determined by sandwich enzyme-linked immunosorbent assay, insulin resistance was determined by homeostasis model assessment for insulin resistance (HOMA-IR). Results of this study indicate that leptin (15.92 ± 10.50 vs.9.43 ± 4.39 pg/ml, p < 0.001), L:A ratio (1.08 ± 1.06 vs.0.42 ± 0.38 pg/ml, p < 0.001), HOMA-IR, the lipid profile, and other metabolic risk factors (waist circumference (WC), waist-to-hip ratio(WHR), body mass index((BMI)), fasting plasma glucose (FPG) level and fasting plasma insulin(FPI)) were significantly higher but HDL, HDL/LDL and adiponectin level (20.55 ± 10.76 vs.30.08 ± 13.08 pg/ml, p < 0.001)were significantly lower in postmenopausal women with metabolic syndrome than in women without the syndrome (p < 0.001). Further, in postmenopausal women with metabolic syndrome, L: A ratio was significantly positive (p < 0.05 or p < 0.001) correlated with WC, BMI, WHR, TG, FPG, TC/HDL, LDL/HDL, FPI and HOMA-IR (p < 0.01), and negatively correlated with HDL and HDL/LDL (p < 0.001). Conclusively L: A ratio was found to be significantly associated with central obesity and other metabolic risk factors so that high L:A ratio may act as a diagnostic marker for metabolic syndrome in postmenopausal women.

Relative contribution of obesity and menopause to the association between serum adiponectin and incident metabolic syndrome.

Metabolic syndrome is closely linked to obesity. Menopause may play a critical role in understanding the pathophysiology of metabolic syndrome in women. We investigated the relative contribution of obesity and menopause to the association between serum adiponectin levels and the development of metabolic syndrome. A prospective cohort study was conducted in which a total of 1,219 women without metabolic syndrome were examined at baseline (2005-2008) and followed up (2008-2011). Women were divided according to tertiles of serum adiponectin levels and menopause status, and then stratified into four groups: the nonobese with high adiponectin; the nonobese with low adiponectin; the obese with high adiponectin; and the obese with low adiponectin. During an average 2.5-year follow-up, 44 premenopausal women (9.8%) and 161 postmenopausal women (20.9%) developed metabolic syndrome. The obese group with low serum adiponectin demonstrated an increased risk for developing metabolic syndrome in both premenopausal (odds ratio [OR] 5.92, 95% confidence interval [CI] 2.24-15.66) and postmenopausal women (OR 4.22, 95% CI 2.41-7.36). However, the inverse association between serum adiponectin levels and incidence of metabolic syndrome was observed in premenopausal women with obesity (OR 0.16, 95% CI 0.03-0.81), but not in postmenopausal women with obesity (OR 0.55, 95% CI 0.27-1.14). High serum adiponectin levels showed no inverse association with metabolic syndrome in postmenopausal women with obesity. These findings may suggest a need for closer management of metabolic risk in postmenopausal women.

Метаболический синдром у пациенток в постменопаузальном периоде

Метаболический синдром у пациенток в постменопаузальном периоде